Study Shows Lyrica Reduces Pain Severity in Chronic Pain Conditions

Study Shows Lyrica Reduces Pain Severity in Chronic Pain Conditions
Patients experiencing chronic pain have shown a significant improvement upon treatment with Lyrica (pregabalin) compared to placebo treated patients, according to a new study analysis. The orally administrated drug is approved by the U.S. Food and Drug Administration (FDA) and European Medicine Agencies (EMA) to treat chronic pain conditions including fibromyalgia (FM), neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), and spinal cord injury (SCI). Its effectiveness for improving pain intensity has been demonstrated in many placebo-controlled trials. Patients with chronic pain often characterize their pain as mild, moderate, or severe, which usually also reflect the degree of pain interference in the patient’s function. In many situations, because the pain categories and function relationship is not linear, scientist believe it is important to understand if treatments that bring about meaningful pain relief can be related to clinically significant changes in function. The analysis report, “Improvement in pain severity category in clinical trials of pregabalin,” published in the Journal of Pain Research, intended to better understand the overall clinical benefit of Lyrica in all FDA-approved chronic pain conditions. Researchers analyzed pain category data collected from 23 placebo-controlled trials of Lyrica therapy for patients with FM (1,623 treated with Lyrica, 937 with placebo), DPN/PHN (2,867 treated with Lyrica, 1,53
Subscribe or to access all post and page content.